From the World Literature
- PDF / 107,691 Bytes
- 8 Pages / 592.44 x 751.18 pts Page_size
- 111 Downloads / 207 Views
NEWS
© 2008 Adis Data Information BV. All rights reserved.
From the World Literature Contents 1. 2. 3. 4. 5. 6. 7.
Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405 Cardiovascular Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407 Diabetes Mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409 Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409 Neurologic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411 Respiratory Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411 Genetic Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412
1. Cancer
ACE Inhibitors May Help Prevent Cancer
Researchers from the Netherlands report that ACE inhibitors and other renin-angiotensin system inhibitors appear to have a protective effect against cancer. They noted that the deletion version of an insertion/deletion polymorphism in the angiotensin I converting enzyme (ACE) gene is associated with an increased plasma level of ACE, which correlates with the levels of angiotensin II and may, therefore, have a role in cancer development. On this basis, they conducted an analysis of data from 7679 individuals who were involved in a population-based, prospective cohort study (the Rotterdam study), including 6670 who had an available ACE insertion/deletion genotype. During follow-up (mean 9.6 years), 730 participants were diagnosed with cancer, including 157 who received an ACE inhibitor or other RAS inhibitor. Among patients homozygous for the ACE deletion (D/D genotype), there was a significant, negative interaction between RAS inhibitors and cancer risk (HR 0.60; p = 0.02), but there was no such interaction among patients with D/ I or I/I genotypes. Specifically, among patients with the D/D genotype, RAS inhibitors were associated with trends towards negative interactions with risks of breast cancer (HR 0.86; p = 0.08), prostate cancer (HR 0.41; p = 0.09), and colorectal cancer (HR 0.45; p = 0.28); risk reductions were greater with high-dose, l
Data Loading...
